Status:
COMPLETED
Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
Lead Sponsor:
William Ondo, MD
Collaborating Sponsors:
Lundbeck LLC
Conditions:
Parkinson Disease
Neurogenic Orthostatic Hypotension
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
This is a double blind placebo controlled trial in Parkinson's disease (PD) patients with neurogenic orthostatic hypotension (NOH). Investigators hypothesize that the study drug (droxidopa) may improv...
Detailed Description
1. This is a double blind placebo controlled trial in PD patients with NOH. The controlled portion consists of two visits (baseline and week 4) and a phone call (week 2). An open label extension will ...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's disease patients with orthostatic hypotension (Systolic Blood Pressure drop of \> 20 mm hg or Diastolic Blood Pressure drop of \>10 mm hg measured at some point) within a month of inclusion.
Exclusion
- Age \>85
- Concurrent use of Midodrine
- Medical conditions that in the opinion of the investigator, might not allow for same completion of the study i.e. unstable angina, neoplasm, etc
Key Trial Info
Start Date :
August 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 2 2022
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT03229174
Start Date
August 23 2018
End Date
February 2 2022
Last Update
September 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Houston Methodist Hospital
Houston, Texas, United States, 77030